SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bajaj Healthcare trades jubilantly on getting exclusive rights to manufacture, market Magnesium L Threonate in India

17 Jan 2025 Evaluate

Bajaj Healthcare is currently trading at Rs. 637.45, up by 75.55 points or 13.45% from its previous closing of Rs. 561.90 on the BSE.

The scrip opened at Rs. 572.85 and has touched a high and low of Rs. 655.00 and Rs. 572.85 respectively. So far 158615 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 655.00 on 17-Jan-2025 and a 52 week low of Rs. 265.00 on 04-Jun-2024.

Last one week high and low of the scrip stood at Rs. 655.00 and Rs. 499.40 respectively. The current market cap of the company is Rs. 2008.69 crore.

The promoters holding in the company stood at 59.19%, while Institutions and Non-Institutions held 3.04% and 37.78% respectively.

Bajaj Healthcare has received exclusive rights for manufacturing, distribution & sales of the finished formulation of the Product Magnesium L Threonate (Magtein) in India from the rights holder, Threotech LLC.

The company will therefore have the rights to manufacture/ market/ distribute/co-market in the Indian market for Magnesium L Threonate (Magtein).

The Company is already supplying the API Magnesium L Threonate (Magtein), to the patent holder in United States of America.

The API is supplied by Bajaj Healthcare for the brand Magtein in the United States of America as an exclusive arrangement. The brand Magtein by Threotech LLC has a sales value of around $438 million.

Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.

Bajaj Healthcare Share Price

329.60 -4.25 (-1.27%)
21-Apr-2026 09:42 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.45
Dr. Reddys Lab 1223.60
Cipla 1230.40
Zydus Lifesciences 929.00
Lupin 2331.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×